Payment overview · 2025
General Payments
$2,253.71
60 reported records · 16 companies
Healthcare provider profile · identity verified
Steven Minter, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · COLUMBIA, SC · NPI 1649431990
Verified facts
What the public records show
CMS Open Payments records show Steven Minter, D.O. received $2,253.71 in general payments during 2025 across 60 reported records.
Novartis Pharmaceuticals Corporation accounted for 69.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Erleada.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Eliquis by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ERLEADA as an associated drug or biological on 32382 records involving 10919 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Erleada by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROMACTA as an associated drug or biological on 47 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Promacta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $1,556.23 | 69.0% | 26 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $135.02 | 6.0% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $87.39 | 3.9% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $82.25 | 3.6% | 4 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $61.40 | 2.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $60.03 | 2.7% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $50.10 | 2.2% | 2 | 2025 |
| ADC THERAPEUTICS AMERICA, INC. | Unresolved — no canonical attribution shown | $40.31 | 1.8% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $34.67 | 1.5% | 2 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.84 | 1.4% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $26.63 | 1.2% | 1 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $20.88 | 0.9% | 1 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $20.63 | 0.9% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $16.91 | 0.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.11 | 0.7% | 1 | 2025 |
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $14.31 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Long term medical supply or device loan | $1,196.40 | 12 |
| Food and Beverage | $1,057.31 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $1,316.07 | 18 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $135.02 | 7 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $111.77 | 6 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $108.25 | 4 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $97.76 | 3 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $66.70 | 3 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $62.80 | 3 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $62.80 | 3 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $61.40 | 4 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $61.40 | 4 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $60.03 | 2 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $50.10 | 2 | 2025 |
Source payment records
|
|||||
| ZYNLONTA Normalized: zynlonta |
Drug | ADC THERAPEUTICS AMERICA, INC. | $40.31 | 2 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $34.67 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $34.15 | 1 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $30.84 | 1 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $30.84 | 1 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $30.84 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $26.63 | 1 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| Tivdak Normalized: tivdak |
Drug | Genmab U.S., Inc. | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ERLEADA erleada |
2025 | Erleada | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
72 | 23 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
72 | 23 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | ERLEADA open payments reported associated product |
CMS Open Payments — General Payments 32382 supporting records · 10919 recipient NPIs · example record 1174257499 |
Erleada · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | PROMACTA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 47 recipient NPIs · example record 1200028032 |
Promacta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
72 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Letrozole | Letrozole | 306 | 89 |
| Acyclovir | Acyclovir | 101 | 26 |
| Dexamethasone | Dexamethasone | 86 | 30 |
| Eliquis | Apixaban | 72 | 23 |
| Hydroxyurea | Hydroxyurea | 64 | 16 |
| Tamoxifen Citrate | Tamoxifen Citrate | 62 | 25 |
| Ondansetron Odt | Ondansetron | 58 | 51 |
| Anastrozole | Anastrozole | 56 | 19 |
| Revlimid | Lenalidomide | 41 | 18 |
| Imatinib Mesylate | Imatinib Mesylate | 37 | suppressed |
| Prednisone | Prednisone | 37 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 20 |
| Potassium Chloride | Potassium Chloride | 33 | 16 |
| Promethazine Hcl | Promethazine Hcl | 32 | 19 |
| Gabapentin | Gabapentin | 28 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 26 | 20 |
| Omeprazole | Omeprazole | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 14 |
| Promacta | Eltrombopag Olamine | 17 | suppressed |
| Dextrose In Lactated Ringers | Dextrose 5%-Lactated Ringers | 16 | suppressed |
| Exemestane | Exemestane | 16 | suppressed |
| Furosemide | Furosemide | 16 | suppressed |
| Brukinsa | Zanubrutinib | 15 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | 15 |
| Allopurinol | Allopurinol | 14 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 14 | 11 |
| Erleada | Apalutamide | 13 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 12 | 11 |
| Abiraterone Acetate | Abiraterone Acetate | 11 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,253.71 · 60 records | Novartis Pharmaceuticals Corporation | AKEEGA, BALVERSA, BESREMI, BLENREP, BRAFTOVI, DARZALEX, DATROWAY, ELAHERE, ERLEADA, Fabhalta, Gavreto, IBRANCE, INLYTA, KISQALI, LORBRENA, LUTATHERA, MEKTOVI, OPDIVO, PADCEV, REBLOZYL, Rezlidhia, SCEMBLIX, TAVALISSE, TECVAYLI, TUKYSA, Tivdak, Trodelvy, Yescarta, ZYNLONTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Erleada play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Celgene Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error